LPTX — Leap Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $75.00m
- $20.08m
- 26
- 21
- 30
- 15
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 3.89 | 52.1 | 115 | 65.5 | 70.6 |
Net Total Receivables | 0.185 | 0.073 | 1.19 | 2.1 | 0.771 |
Prepaid Expenses | |||||
Total Current Assets | 4.24 | 52.3 | 117 | 68 | 71.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.15 | 0.593 | 0.495 | 0.689 | 0.262 |
Other Long Term Assets | |||||
Total Assets | 7.45 | 54.4 | 118 | 70.4 | 72.8 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.49 | 7.37 | 9.99 | 11.2 | 12.7 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.2 | 7.72 | 10 | 11.5 | 12.7 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -1.75 | 46.7 | 108 | 58.9 | 60.1 |
Total Liabilities & Shareholders' Equity | 7.45 | 54.4 | 118 | 70.4 | 72.8 |
Total Common Shares Outstanding |